Hi,
Happy Winter Solstice.
Very soon the days can only get brighter and the sun rise higher, at least in the Northern Hemisphere.
ASH 2018 was amazing for its bounty of CLL promising research. We did over 50 interviews that we will posting on the website over the coming weeks.
This week we posted an interview on the CLL Society website (CLLSociety.org) with Professor Hillmen of Leeds concerning the timing of ibrutinib and obinutuzumab.
It turns out that response rates and depth of response were much better for patients who were on ibrutinib for a year and then received the antibody compared to those who started them both together.
We keep learning more and more
Stay strong.
We are all in this together.
Brian Koffman MDCM DCFP, DABFM, MS Ed
